File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A prospective, randomized, placebo-controlled trial on the use of mifepristone with sublingual or vaginal misoprostol for medical abortions of less than 9 weeks gestation

TitleA prospective, randomized, placebo-controlled trial on the use of mifepristone with sublingual or vaginal misoprostol for medical abortions of less than 9 weeks gestation
Authors
Issue Date2003
PublisherOxford University Press. The Journal's web site is located at http://humrep.oxfordjournals.org/
Citation
Human Reproduction, 2003, v. 18 n. 11, p. 2315-2318 How to Cite?
AbstractBackground: A combination of mifepristone and misoprostol provides an effective method of medical abortion for early pregnancy. This is the first randomized trial comparing the use of sublingual misoprostol with vaginal misoprostol in combination with mifepristone for termination of early pregnancies up to 63 days. Methods: A total of 224 women who requested legal termination of pregnancy up to 63 days were randomized by computer-generated list into two groups and given 200 mg of oral mifepristone followed 48 h later by either 800 μg of sublingual (n = 112) or vaginal (n = 112) misoprostol. Results: Complete abortion occurred in 98.2% (95% CI: 93-99) of women in the sublingual group and 93.8% (95% CI: 88-97) in the vaginal group. There were three ongoing pregnancies in the vaginal group but none in the sublingual group. The median duration of vaginal bleeding was 17 days. There was no serious complication. Fever, chills and gastrointestinal side-effects (nausea, vomiting and diarrhoea) were significantly more common in the sublingual group. Conclusions: The combination of mifepristone and misoprostol is effective for medical abortion up to 63 days. Both the sublingual and vaginal are effective routes of administration. Further randomized trials are required to find out the optimal dose of sublingual misoprostol that can give the highest complete abortion rate and lowest incidence of side-effects.
Persistent Identifierhttp://hdl.handle.net/10722/173270
ISSN
2015 Impact Factor: 4.621
2015 SCImago Journal Rankings: 2.271
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorTang, OSen_US
dc.contributor.authorChan, CCWen_US
dc.contributor.authorNg, EHYen_US
dc.contributor.authorLee, SWHen_US
dc.contributor.authorHo, PCen_US
dc.date.accessioned2012-10-30T06:28:57Z-
dc.date.available2012-10-30T06:28:57Z-
dc.date.issued2003en_US
dc.identifier.citationHuman Reproduction, 2003, v. 18 n. 11, p. 2315-2318en_US
dc.identifier.issn0268-1161en_US
dc.identifier.urihttp://hdl.handle.net/10722/173270-
dc.description.abstractBackground: A combination of mifepristone and misoprostol provides an effective method of medical abortion for early pregnancy. This is the first randomized trial comparing the use of sublingual misoprostol with vaginal misoprostol in combination with mifepristone for termination of early pregnancies up to 63 days. Methods: A total of 224 women who requested legal termination of pregnancy up to 63 days were randomized by computer-generated list into two groups and given 200 mg of oral mifepristone followed 48 h later by either 800 μg of sublingual (n = 112) or vaginal (n = 112) misoprostol. Results: Complete abortion occurred in 98.2% (95% CI: 93-99) of women in the sublingual group and 93.8% (95% CI: 88-97) in the vaginal group. There were three ongoing pregnancies in the vaginal group but none in the sublingual group. The median duration of vaginal bleeding was 17 days. There was no serious complication. Fever, chills and gastrointestinal side-effects (nausea, vomiting and diarrhoea) were significantly more common in the sublingual group. Conclusions: The combination of mifepristone and misoprostol is effective for medical abortion up to 63 days. Both the sublingual and vaginal are effective routes of administration. Further randomized trials are required to find out the optimal dose of sublingual misoprostol that can give the highest complete abortion rate and lowest incidence of side-effects.en_US
dc.languageengen_US
dc.publisherOxford University Press. The Journal's web site is located at http://humrep.oxfordjournals.org/en_US
dc.relation.ispartofHuman Reproductionen_US
dc.rightsHuman Reproduction. Copyright © Oxford University Press.-
dc.subject.meshAbortifacient Agents, Nonsteroidal - Administration & Dosage - Adverse Effectsen_US
dc.subject.meshAbortifacient Agents, Steroidal - Adverse Effects - Therapeutic Useen_US
dc.subject.meshAbortion, Induceden_US
dc.subject.meshAdministration, Intravaginalen_US
dc.subject.meshAdministration, Sublingualen_US
dc.subject.meshAdulten_US
dc.subject.meshDrug Therapy, Combinationen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshMifepristone - Adverse Effects - Therapeutic Useen_US
dc.subject.meshMisoprostol - Administration & Dosage - Adverse Effectsen_US
dc.subject.meshPlacebosen_US
dc.subject.meshPregnancyen_US
dc.subject.meshPregnancy Trimester, Firsten_US
dc.subject.meshTreatment Outcomeen_US
dc.titleA prospective, randomized, placebo-controlled trial on the use of mifepristone with sublingual or vaginal misoprostol for medical abortions of less than 9 weeks gestationen_US
dc.typeArticleen_US
dc.identifier.emailNg, EHY:nghye@hkucc.hku.hken_US
dc.identifier.emailHo, PC:pcho@hku.hken_US
dc.identifier.authorityNg, EHY=rp00426en_US
dc.identifier.authorityHo, PC=rp00325en_US
dc.description.naturelink_to_OA_fulltexten_US
dc.identifier.doi10.1093/humrep/deg475en_US
dc.identifier.pmid14585880-
dc.identifier.scopuseid_2-s2.0-0242606903en_US
dc.identifier.hkuros88147-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0242606903&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume18en_US
dc.identifier.issue11en_US
dc.identifier.spage2315en_US
dc.identifier.epage2318en_US
dc.identifier.isiWOS:000186447500015-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridTang, OS=7006723402en_US
dc.identifier.scopusauthoridChan, CCW=26643394500en_US
dc.identifier.scopusauthoridNg, EHY=35238184300en_US
dc.identifier.scopusauthoridLee, SWH=26030998000en_US
dc.identifier.scopusauthoridHo, PC=7402211440en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats